Brain Tumor Drugs Global Market Report 2024

The brain tumor drugs market size has grown strongly in recent years. It will grow from $3.55 billion in 2023 to $3.81 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The historical growth can be attributed to several factors, including a rising prevalence of neurological disorders, increased healthcare expenditure, a higher number of approvals for oncology (cancer) drugs, an upsurge in pharmaceutical research and development (R&D) expenditure, and advancements in cancer drug discovery.

The brain tumor drugs market size is expected to see strong growth in the next few years. It will grow to $5.01 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. Forecasted growth is attributed to rising cancer rates, increased healthcare spending, a growing elderly population, a robust drug pipeline, and revised FDA regulations for biologics. Major trends include investing in drug combinations for brain tumor treatment, adopting phase zero clinical trials for efficacy improvement, using technology in drug delivery for enhanced effectiveness, focusing on expanding cell and gene therapy, and engaging in strategic mergers and acquisitions.

The primary catalyst fueling the expansion of the Brain Tumor drugs market is the escalating prevalence of Neurological Disorders on a global scale. These disorders have become increasingly prevalent due to factors such as longer life expectancy, heightened exposure to infections, and sedentary lifestyles. For instance, as reported by the National Brain Tumor Society, approximately 700,000 individuals in the United States are currently affected by primary brain tumors, with an additional 86,000 expected to receive diagnoses. This growing population of individuals with neurological disorders, including brain tumors, is directly contributing to the increased demand for drugs utilized in their treatment, thereby fostering the growth of the brain tumor drugs market.

The surge in the number of patients undergoing chemotherapy is poised to drive the continued expansion of brain tumor drugs. Chemotherapy, a vital medical approach employing potent drugs to target and eradicate rapidly dividing cells such as cancer cells, remains a cornerstone treatment for brain tumors. The development and accessibility of effective chemotherapy drugs significantly influence the overall success of treatment regimens. The efficacy of chemotherapy profoundly impacts patient survival rates and enhances their quality of life, exerting a substantial influence on the market landscape. For instance, based on data from the Centers for Disease Control and Prevention in July 2023, over 1 million cancer patients in the United States undergo chemotherapy or radiation therapy annually. Consequently, the escalating number of patients opting for chemotherapy serves as a pivotal driver propelling the growth trajectory of the brain tumor drugs market.

Companies within the brain tumor drugs market are increasingly turning towards nanotechnology for treatment methodologies. Nanoparticles are being utilized as carriers for drugs, delivering them directly to cancer cells or into the tumor, yielding advantages such as reduced drug dosage, enhanced shelf life, and minimized toxicity. Some nanodrugs have proven effective in surmounting the blood-brain barrier, a historically significant challenge in treating brain tumors. Notably, nanoparticles such as Liposomes have facilitated targeted drug delivery to the core of cancer cells. Moreover, when coated with transferrin, these particles can breach the blood-brain barrier. Esteemed industry players such as GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Merck & Company Inc., Pfizer, Inc., and Celgene Corporation are actively embracing this technology to advance medication and treatment techniques.

Key industry entities within the brain tumor drugs market are heavily invested in the development and approval of novel drugs, aiming to gain a competitive advantage. Drug approvals represent the regulatory process by which government health agencies authorize the marketing, sale, and prescription of new medications for specific medical conditions. For example, in June 2022, the United States Food and Drug Administration granted accelerated approval for a novel treatment combination incorporating the oral drugs dabrafenib (Tafinlar) and trametinib (Mekinist) for advanced brain tumors exhibiting the BRAF V600E mutation. This approval extends to both adult and pediatric patients with high- and low-grade gliomas that have progressed post-prior treatments. Encouraging results from clinical trials revealed significant tumor reduction among patients receiving the combination therapy. Notably, positive responses were observed in 33% of high-grade glioma patients, 50% of low-grade glioma patients, and 25% of pediatric glioma patients. The BRAF V600E mutation is prevalent across various glioma types, including low-grade gliomas, pleomorphic xanthoastrocytomas (PXA), gangliogliomas, and pilocytic astrocytomas.

In December 2021, Sanofi, a French pharmaceutical company, completed the acquisition of Amunix Pharmaceuticals Inc. for a total of $1 billion. This strategic move positions Sanofi to advance its efforts in developing potentially transformative cancer therapies, particularly in the field of immuno-oncology. Amunix Pharmaceuticals Inc., a U.S.-based pharmaceutical company, brings valuable assets, including brain tumor drugs, to bolster Sanofi's capabilities in the oncology space.

Major companies operating in the brain tumor drugs market report are F. Hoffmann-La Roche Ltd., Novartis AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc., CordenPharma, Eisai Co., Ltd., Emcure Pharmaceuticals Limited, AstraZeneca, Y-mAbs Therapeutics, Roche India, Novartis Oncology, Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd., Apikos Pharma, Kolaz Biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals (Japan), Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca PLC, GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, Sandoz AG, Eurofarma Laboratórios S.A., TUTEUR Argentina, The Takeda Pharmaceutical Company Limited, Pierre Fabre Group, Celnova Pharma, Pfizer S.R.L., Teva Pharmaceutical Industries Ltd., BIOPHARMA-MEA, NeoTX, AID Genomics Limited, GlaxoSmithKline PLC, Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Eurolab, Aspen, Adcock Ingram.

North America was the largest region in the brain tumor drugs market in 2023. Middle East is expected to be the fastest-growing region in the global brain tumor drugs market share during the forecast period. The regions covered in the brain tumor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the brain tumor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Key drugs in the realm of brain tumor treatment include temozolomide, carmustine, cisplatin, bevacizumab, gefitinib, and erlotinib. Temozolomide, for instance, is designed to treat specific types of brain cancer such as glioblastomamultiforme and anaplastic astrocytoma. These drugs fall under the category of antineoplastics, focusing on combating cancer. Various types of brain tumors, such as medulloblastoma, astrocytoma, oligodendroglioma, primitive neuroectodermal (PNET), and others such as glioma, acoustic neuroma, and meningioma, are addressed using these drugs. The sectors benefiting from these treatments include hospital pharmacies, clinics, and other healthcare facilities.

The brain tumor drugs market research report is one of a series of new reports that provides brain tumor drugs market statistics, including brain tumor drugs industry global market size, regional shares, competitors with a brain tumor drugs market share, detailed brain tumor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the brain tumor drugs industry. This brain tumor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The brain tumor drugs market consists of sales Afinitor (Everolimus), Afinitor Disperz (Everolimus), Belzutifan, and Bevacizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.